Parkinson's disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the SubstantiaNigra. The pathogenesis of this disorder remains poorly understood and PD is still incurable. Currentdrug treatmentsare aimedprimarily for the treatmentof symptoms to improve the quality of life. Therefore, there is a need to find out new therapeutic strategies that not only provide symptomatic relief but also halt or reverse the neuronal damage hampering PD progression. Oxidative stress has been identified as one of the major contributors for the nigral loss in both sporadic and genetic forms of PD. In this review we first evaluate the current literature that link oxidative stress and mitochondrial dysfunction to PD. We then consider the results obtained through the treatmentof animal modelsor PD patients withmolecules that prevent oxidative stress or reduce mitochondrial dysfunction.
Anti-oxidants in Parkinson's disease therapy: a critical point of view
FILOGRANA, ROBERTA;BELTRAMINI, MARIANO;BUBACCO, LUIGI;BISAGLIA, MARCO
2016
Abstract
Parkinson's disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the SubstantiaNigra. The pathogenesis of this disorder remains poorly understood and PD is still incurable. Currentdrug treatmentsare aimedprimarily for the treatmentof symptoms to improve the quality of life. Therefore, there is a need to find out new therapeutic strategies that not only provide symptomatic relief but also halt or reverse the neuronal damage hampering PD progression. Oxidative stress has been identified as one of the major contributors for the nigral loss in both sporadic and genetic forms of PD. In this review we first evaluate the current literature that link oxidative stress and mitochondrial dysfunction to PD. We then consider the results obtained through the treatmentof animal modelsor PD patients withmolecules that prevent oxidative stress or reduce mitochondrial dysfunction.File | Dimensione | Formato | |
---|---|---|---|
Bisaglia-revised1.pdf
accesso aperto
Tipologia:
Preprint (submitted version)
Licenza:
Accesso libero
Dimensione
531.72 kB
Formato
Adobe PDF
|
531.72 kB | Adobe PDF | Visualizza/Apri |
Bisaglia32-CurrNeuropharm.pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Creative commons
Dimensione
640.41 kB
Formato
Adobe PDF
|
640.41 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.